Literature DB >> 15090098

Influence of clinical and economical factors on the expert rating of appropriateness of preoperative use of recombinant erythropoietin in elective orthopedic surgery patients.

Patrick Taffé1, Bernard Burnand, Vincent Wietlisbach, John-Paul Vader.   

Abstract

To evaluate the relative impact of clinical factors and health care environment resources on the expert ratings of appropriateness of preoperative erythropoietin in elective orthopedic surgery, the authors analyzed 6905 individual votes on 496 clinical scenarios from 14 experts, applying a multivariate logistic model. Sixty-six percent of the indications were appropriate when resource constraints (RC) were not considered and 53% when they were, resulting in a drop in the median vote of 2 points on a 9-point scale (P < 0.05). Initial hemoglobin level, expected perioperative blood loss, and RC were by far the most significant contributors to the model (P < 0.01), but other factors (i.e., clinical specialty of the expert, prior history of transfusion reactions, patient age, cardiovascular disease, anemia of chronic disease) also contributed significantly (P< 0.01). For assessing appropriateness of care, this study confirms the need for detailed clinical scenarios and a multidisciplinary panel carefully selected to reflect those involved in the interventions under consideration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15090098     DOI: 10.1177/0272989X04263153

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  2 in total

Review 1.  Developing clinical guidelines: a challenge to current methods.

Authors:  Rosalind Raine; Colin Sanderson; Nick Black
Journal:  BMJ       Date:  2005-09-17

2.  The impact of patient preferences and costs on the appropriateness of spinal manipulation and mobilization for chronic low back pain and chronic neck pain.

Authors:  Patricia M Herman; Margaret D Whitley; Gery W Ryan; Eric L Hurwitz; Ian D Coulter
Journal:  BMC Musculoskelet Disord       Date:  2019-11-07       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.